Welcome to our dedicated page for Ibio SEC filings (Ticker: IBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The iBio, Inc. (NASDAQ: IBIO) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including Forms 10‑K, 10‑Q and 8‑K, as they appear on the EDGAR system. iBio is a preclinical-stage biotechnology company that uses AI and advanced computational biology to develop precision antibody therapies for cardiometabolic diseases, obesity, cancer and other hard-to-treat diseases, and its filings offer detailed insight into this strategy.
Through annual and quarterly reports, investors can review iBio’s description of its AI Drug Discovery Platform, preclinical pipeline programs such as IBIO‑610 and IBIO‑600, risk factors, liquidity and capital resources. Current reports on Form 8‑K capture material events, including financing transactions, Nasdaq listing compliance updates, new preclinical data disclosures, changes to corporate presentations and the results of annual stockholder meetings. The company’s definitive proxy statements (DEF 14A) provide information on board structure, executive compensation and governance matters.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand topics such as preclinical data updates, capital-raising terms, and changes in risk disclosures. Real-time updates ensure that new IBIO filings, including Form 4 insider transaction reports when available, appear promptly in the feed.
By using this IBIO filings page, investors and researchers can efficiently navigate iBio’s regulatory history, from its business description and pipeline details to financing structures and governance decisions, while AI-generated overviews make complex SEC documents more accessible.
iBio, Inc. entered into a new at-the-market stock offering program with Jefferies LLC, allowing sales of up to
iBio also terminated its prior at-the-market program with Chardan Capital Markets and Craig-Hallum Capital Group, which had permitted issuances of up to
iBio, Inc. filed a shelf registration on Form S-3 to offer up to $200,000,000 of securities, including up to $100,000,000 of Common Stock that may be offered under an Open Market Sales Agreement with Jefferies LLC dated February 27, 2026, to be sold from time to time as market conditions permit.
The prospectus states the offering may include Common Stock, Preferred Stock, debt securities, warrants or units. As context, the company reported 34,543,561 shares outstanding as of February 24, 2026 and 127,598,048 shares issuable upon exercise of outstanding warrants as of February 24, 2026.
iBio, Inc. received an updated Schedule 13G/A from ADAR1 Capital Management, related entities, and Daniel Schneeberger reporting beneficial ownership of up to 1,351,671 shares of common stock, or 4.4% of the company’s shares outstanding as of December 31, 2025.
The position includes 390,864 shares held by ADAR1 Partners, LP, smaller amounts in other managed accounts, and 956,140 shares underlying milestone warrants. The filers state the securities are held in the ordinary course of business and not for changing or influencing control, and they now report ownership of 5 percent or less of the class.
iBio, Inc. received an amended Schedule 13G filing showing that Logos Global Management LP and affiliated entities report beneficial ownership of 1,500,000 shares of iBio common stock. This stake represents 4.6% of the outstanding common shares, based on 32,540,942 shares outstanding as of January 30, 2026, as cited from iBio’s Form S-3.
The filing attributes the same 1,500,000-share, 4.6% position to Logos Global Management LP, Logos Global Management GP LLC, Logos Global Master Fund LP, Logos GP LLC, and Arsani William, with shared voting and dispositive power over all reported shares and no sole power. The reporting persons state the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of iBio. They also jointly file while expressly disclaiming group status and beneficial ownership beyond their pecuniary interest.
iBio, Inc. received an amended Schedule 13G/A from Lynx1 Capital Management LP and Weston Nichols stating they no longer beneficially own any of the company’s common stock. The filing reports 0 shares beneficially owned and a 0% ownership stake, with no voting or dispositive power over any shares.
The reporting persons also certify that the securities referenced were not acquired and are not held for the purpose of changing or influencing control of iBio, Inc., and are not part of any control-related transaction.
iBio, Inc. reported a larger net loss while significantly strengthening its balance sheet as it advances its AI-driven obesity pipeline. For the three months ended December 31, 2025, the company generated no revenue, versus $200,000 a year earlier, and posted a net loss of $8.99 million as research and development and general and administrative expenses more than doubled.
For the six-month period, revenue was $100,000 and the net loss widened to $14.71 million. Operating cash outflows were $10.91 million, but financing activities, including sales of pre-funded warrants and common stock, provided $55.49 million, lifting cash and cash equivalents to $28.67 million and investments in debt securities to $24.03 million as of December 31, 2025.
The company recorded a $2.5 million impairment on an oncology intangible asset as it sharpened its focus on cardiometabolic and obesity antibodies. With approximately $52.7 million in cash and investments at period end and an additional $26 million raised in a January 2026 private placement, iBio believes it can fund operations for at least 12 months as it prepares IBIO-600 for Phase 1a trials in the first half of 2026 and targets first-in-human studies for IBIO-610 in early 2027.
iBio, Inc. reported a larger loss for its fiscal second quarter ended December 31, 2025 while strengthening its balance sheet and advancing its obesity-focused antibody pipeline. The company completed a $26 million private placement led by a biotech investor, receiving net proceeds of approximately $24.4 million in January 2026 and extending its cash runway into the third quarter of fiscal year 2028.
For the quarter, iBio recognized no revenue, compared with $0.2 million a year earlier. Research and development expenses rose to $4.3 million from $1.9 million, driven by higher spending on consultants, outside services, and personnel to progress IBIO-600, IBIO-610 and other preclinical assets. General and administrative expenses increased to approximately $5.2 million from $2.7 million, primarily due to an impairment of the IBIO-101 intangible asset, resulting in a net loss of $8,993 thousand versus $4,364 thousand.
iBio held $52.7 million in cash, cash equivalents and investments in debt securities as of December 31, 2025. Management highlighted initiation of CMC development and toxicology studies for IBIO-610 and IBIO-600 as key steps toward planned human clinical trials.
iBio, Inc. is registering up to 11,061,738 shares of common stock for resale by existing investors, including 1,408,481 already-issued shares and up to 9,653,257 shares underlying pre-funded warrants.
The company will not sell any shares in this offering and will not receive proceeds from stockholder resales, other than any cash paid if pre-funded warrants are exercised at $0.001 per share. These securities stem from a January 2026 private placement that generated approximately
iBio is a preclinical-stage biotechnology company using AI-driven antibody discovery to develop cardiometabolic and obesity therapies, with its IBIO-610 program expected to enter first-in-human trials in early
iBio, Inc. is registering 11,061,738 shares of common stock for resale by existing investors following a January 2026 private placement. The shares include 1,408,481 already issued common shares and up to 9,653,257 shares issuable upon exercise of pre-funded warrants with a $0.001 exercise price.
The company previously raised approximately $26 million in gross proceeds in the private placement at a purchase price of $2.35 per common share. iBio will not receive proceeds from resale of these shares, other than nominal amounts if the pre-funded warrants are exercised. The filing fulfills registration rights granted to the investors and may increase potential share sales into the market.